[1] Raimkylov K M, Kuttubaev O T, Toigombaeva V S. Epidemiological analysis of the distgribution of cystic and alveolar echinococcosis in osh oblast in the kyrgyz republic, 2000–2013. J Helminthol,2015, 89(6):651-654. [2] Vuitton D A, Azizi A, Richou C, et al. Current interventional strategy for the treatment of hepatic alveolar echinococcosis. Expert Rev Anti-inf,2016, 14(12):1179-1194. [3] 才让卓玛, 南嘉格列, 李晓君,等. 常规彩超与超声造影诊断肝泡型包虫病效能比较. 实用肝脏病杂志, 2018, 21(2):305-306. [4] Azizi A, Blagosklonov O, Lounis A, et al. Alveolar echinococcosis: correlation between hepatic MRI findings and FDG-PET/CT metabolic activity. Abdom Imaging, 2015, 40(1):56-63. [5] Felix L, Waneck F, Auer H . FDG-PET/MR imaging in alveolar echinococcosis. Int J Infect Dis,2017, 64(6):67-68. [6] 中国医师协会外科医师分会包虫病外科专业委员会. 肝两型包虫病诊断与治疗专家共识(2015版). 中华消化外科杂志, 2015, 14(4):253-264. [7] Ammann R W, Stumpe K D M, Grimm F, et al. Outcome after discontinuing long-term benzimidazole treatment in 11 patients with non-resectable alveolar echinococcosis with negative FDG-PET/CT and anti-emII/3-10 serology. Plos Neglect Trop D, 2015, 9(9):1-14. [8] Zheng JJ, Wang J, Zhao JQ, et al. Diffusion-weighted MRI for the initial viability evaluation of parasites in hepatic alveolar echinococcosis: comparison with positron emission tomography. Korean J Radiol,2018, 19(1):40-46. [9] Joliat G R, Melloul E, Petermann D, et al. Outcomes after liver resection for hepatic alveolar echinococcosis: a single-center cohort study. World J Surg, 2015, 39(10):2529-2534. [10] Khan W, Khan J, Rahman A, et al. Albendazole in the treatment of hymenolepiasis in school children. Pak J Pharm Sci, 2018, 31(1):305-309. [11] Gottstein B, Wang J, Boubaker G , et al. Susceptibility versus resistance in alveolar echinococcosis (larval infection with echinococcus multilocularis). Vet Parasitol, 2015, 213(3):103-109. [12] Bakir H Y , Ah A R , Mahmoud A E , et al. M-RNA gene expression of IFN-γ and IL-10 during intestinal phase of trichinella spiralis after myrrh and albendazole treatment. Iran J Parasitol, 2017, 12(2):188-195. [13] Atayi Z ,Borji H , Moazeni M , et al. Zataria multiflora, would attenuate the hepatotoxicity of long-term albendazole treatment in mice with cystic echinococcosis. Parasitol Int, 2018, 67(2):184-187. [14] Abulaihaiti M , Wu X W , Qiao L , et al. Efficacy of albendazole-chitosan microsphere-based treatment for alveolar echinococcosis in mice. Plos Neglect Trop D, 2015, 9(9):15-16. [15] Corsini M, Geissbühler U, Howard J, et al. Clinical presentation, diagnosis, therapy and outcome of alveolar echinococcosis in dogs. Vet Rec, 2015, 177(22):569-574. [16] Li H, Song T, Qin Y, et al. Efficiency of liposomal albendazole for the treatment of the patients with complex alveolar echinococcosis: a comparative analysis of CEUS, CT, and PET/CT. Parasitol Res, 2015, 114(11):4175-4180. [17] 李肖红, 张奇洲, 秦永德,等. 18F-FDG PET/CT显像评价肝泡型包虫病阿苯达唑脂质体治疗的疗效. 中华核医学与分子影像杂志, 2018, 38(2):101-103. [18] 王静, 丁爽, 刘文亚,等. MR扩散加权成像评价肝脏泡状棘球蚴病生物学活性的价值. 中华放射学杂志, 2015, 49(2):103-106. [19] Kratzer W, Gruener B, Kaltenbach T E, et al. Proposal of an ultrasonographic classification for hepatic alveolar echinococcosis: echinococcosis multilocularis ulm classification-ultrasound. World J Gastroenterol, 2015, 21(43):12392-402. [20] 任东栋, 楼岑, 牟达,等. 18F-FDG PET/CT显像在血清CA19-9升高者中筛查恶性肿瘤的应用价值. 中华核医学与分子影像杂志, 2016, 36(2):186-187. |